UMBILICAL MESENCHYMAL STROMAL CELLS AS CELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK (UC-CISS II): A MULTI-CENTER, DOUBLE-BLIND, PHASE II RANDOMIZED CONTROLLED TRIAL

Registry ID

UC-CISS II

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

OTTAWA HOSPITAL RESEARCH INSTITUTE

Start date

2025-02-18

Last update

2022-02-24

Conditions

• SEPTIC SHOCK

Related clinical trials

• BETA-BLOCKER THERAPY VERSUS STANDARD CARE IN PATIENTS WITH SEPTIC SHOCK: A PILOT RANDOMIZED CONTROLLED TRIAL UTILIZING PREDICTIVE ENRICHMENT WITH POINT-OF-CARE ULTRASOUND
• PRAGMATIC PEDIATRIC TRIAL OF BALANCED VERSUS NORMAL SALINE FLUIDS IN SEPSIS (PROMPT BOLUS)
• HEPARIN ANTICOAGULATION TO IMPROVE OUTCOMES IN SEPTIC SHOCK: THE HALO INTERNATIONAL PHASE II RCT
• TREATMENT OF SEPTIC SHOCK BY INHIBITING AUTODIGESTION AND PRESERVING GUT INTEGRITY WITH ENTERIC LB1148 (SSAIL STUDY)
• CELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK (CISS)

View on source registry